BioPharmSignal logoBioPharmSignal

Biotech News

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

Day One Biopharmaceuticals (DAWN)Day One BiopharmaceuticalsEarnings

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid

Related news

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Day One Biopharmaceuticals

Pediatric and Rare Oncology Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types. OJEMDA OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an...

Recent company news

DAWNDay One Biopharmaceuticals2026-03-06 13:30 EST

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

DAWNDay One Biopharmaceuticals2026-02-24 21:00 EST

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

DAWNDay One Biopharmaceuticals2026-02-10 13:30 EST

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

DAWNDay One Biopharmaceuticals2026-01-11 22:00 EST

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

DAWNDay One Biopharmaceuticals2026-01-06 14:02 EST

Day One Completes Acquisition of Mersana Therapeutics

Stock data

Close
21.53 USD
Market cap
2.22B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States